Joseph Ye, MD
Medical Oncology · Olympia, WANPI 1700881422
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 16.9%. Reporting peaked in 2022 at $27,377 and has fallen 50.2% since, to $13,636 in 2025. Among medical oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,487 payments — averaging $77.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Genentech USA, Inc.$7K
- AbbVie$7K
- Karyopharm Therapeutics Inc.$7K
- Rigel Pharmaceuticals, Inc.$6K
- Astellas Pharma Global Development$6K
- plus $62K from 54 others
Across 307 payments — averaging $15,909 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.3M
- AbbVie$1.2M
- Morphosys AG$402K
- Incyte Corporation$364K
- Seagen Inc.$103K
- Bristol Myers Squibb$102K
- plus $373K from 10 others
What the payments were for
- Consulting fees$62,34054%
- Speaking & faculty fees$13,10611%
- Travel & lodging$4,5834%
- Food & beverage$31,88928%
- Education$2,9233%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,841 in reported general payments places this provider in the 90th percentile of 162 medical oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 33 | $645,637 |
| Lenalidomide | 38 | $443,303 |
| IbrancePalbociclib | 27 | $419,300 |
| RevlimidLenalidomide | 19 | $326,593 |
| NinlaroIxazomib Citrate | 25 | $323,463 |
| TagrissoOsimertinib Mesylate | 16 | $237,812 |
| PromactaEltrombopag Olamine | 16 | $233,213 |
| ImbruvicaIbrutinib | 12 | $196,670 |
| XtandiEnzalutamide | 13 | $189,135 |
| DopteletAvatrombopag Maleate | 12 | $148,929 |
| VenclextaVenetoclax | 12 | $123,762 |
| Lupron DepotLeuprolide Acetate | 13 | $50,270 |
| EliquisApixaban | 50 | $49,771 |
| XareltoRivaroxaban | 46 | $32,009 |
| ZarxioFilgrastim-Sndz | 14 | $29,432 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $2,257 | $645,63733 claims |
| PfizerIbrance, Eliquis | $2,224 | $469,07177 claims |
| Bristol Myers SquibbRevlimid | $3,189 | $326,59319 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $162 | $323,46325 claims |
| AstraZenecaTagrisso | $19,421 | $237,81216 claims |
| NovartisPromacta | $3,311 | $233,21316 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $946 | $196,67012 claims |
| Astellas Pharma US IncXtandi | $1,976 | $189,13513 claims |
| AbbVieVenclexta, Lupron Depot | $6,562 | $174,03225 claims |
| Johnson & JohnsonXarelto | $771 | $32,00946 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Olympia
- Ahmad ForaOlympia$16K
- Hakan KayaSpokane$2.2M
- Bart ScottSeattle$1.3M
- William BensingerLakewood$1.2M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.